Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary Intercept Pharmaceuticals Provides Regulatory and Business Update
NEW YORK , March 26, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the rescheduling of its advisory committee
View HTML
Toggle Summary Intercept to Present at the Cowen 40th Annual Health Care Conference
NEW YORK , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski , M.D., President and
View HTML
Toggle Summary Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Issues 2020 Operating Expense Guidance and Provides Business Update
Worldwide Ocaliva net sales of $249.6 million for the full year 2019, representing 40% growth over the prior year Our NDA was the first accepted by the FDA for liver fibrosis due to NASH Completed enrollment of REVERSE, our Phase 3 study evaluating OCA for the treatment of compensated cirrhosis due
View HTML
Toggle Summary Intercept to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
NEW YORK , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2019 financial
View HTML
Toggle Summary Intercept Completes Enrollment of Phase 3 REVERSE Study Evaluating Obeticholic Acid for the Treatment of Compensated Cirrhosis due to NASH
NEW YORK , Jan. 29, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has completed patient enrollment in
View HTML
Toggle Summary Intercept to Present at the 38th Annual J.P. Morgan Healthcare Conference
NEW YORK , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski , M.D., President and
View HTML
Toggle Summary Intercept Provides Regulatory Update
Company submits Marketing Authorization Application to the European Medicines Agency for obeticholic acid in patients with fibrosis due to NASH FDA notifies Intercept of tentative date for previously announced Advisory Committee meeting NEW YORK , Dec.
View HTML
Toggle Summary Intercept to Host NASH Commercial Day for Investors on December 16, 2019 in New York
NEW YORK , Dec. 10, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will host a NASH Commercial Day for
View HTML
Toggle Summary Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet
NEW YORK , Dec. 05, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the positive results from the interim
View HTML
Toggle Summary Intercept Pharmaceuticals Appoints Jason Campagna as Chief Medical Officer
NEW YORK , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Jason Campagna , M.D.,
View HTML